Table 1.
Demographic and Clinical Characteristics of Patients in GOULD
| LDL‐C Cohort (n=4452) | PCSK9 Inhibitor Cohort (n=554) | P Value | |
|---|---|---|---|
| Age, y | 68.0±9.9 (4451) | 65.9±9.7 (554) | <0.001 |
| Men | 60.9% (2711/4452) | 56.0% (310/554) | 0.025 |
| White race | 85.5% (3807/4452) | 91.2% (505/554) | <0.001 |
| Current smokers | 12.2% (514/4205) | 6.3% (32/507) | <0.001 |
| LDL‐C, mg/dL | 101.1±29.8 (4415) | 79.3±52.4 (538) | <0.001 |
| Body mass index, kg/m2 | 30.6±6.2 (4412) | 30.2±5.3 (546) | 0.070 |
| Estimated 10‐y risk of recurrent ASCVD event (%) | 26.4±19.2 (4452) | 20.6±16.6 (554) | <0.001 |
| Married | 64.3% (2652/4126) | 72.1% (387/537) | <0.001 |
| College or professional degree | 34.5% (1419/4108) | 43.8% (235/537) | <0.001 |
| Annual household income ≥$75 000 | 25.2% (1034/4109) | 37.1% (199/537) | <0.001 |
| Type of health insurance | |||
| Private | 29.4% (1192/4050) | 37.9% (202/533) | <0.001 |
| Medicare | 65.2% (2641/4050) | 58.5% (312/533) | 0.002 |
| Medicaid | 10.8% (436/4050) | 4.9% (26/533) | <0.001 |
| How much per month do you spend on cholesterol‐lowing medications? | <0.001 | ||
| <$25 | 76.7% (2772/3613) | 43.1% (195/452) | |
| $25–$49 | 15.1% (546/3613) | 15.0% (68/452) | |
| $50–$99 | 4.9% (177/3613) | 17.7% (80/452) | |
| $100–$249 | 2.6% (93/3613) | 9.1% (41/452) | |
| $250 or more | 0.7% (25/3613) | 15.0% (68/452) | |
| Moderate or vigorous physical activity | 0.050 | ||
| None | 21.5% (870/4053) | 13.8% (74/538) | |
| 1 or 2 times per wk | 27.4% (1111/4053) | 26.6% (143/538) | |
| 3 or 4 times per wk | 28.2% (1142/4053) | 32.7% (176/538) | |
| 5 to 7 times per wk | 20.2% (819/4053) | 24.5% (132/538) | |
| More than 7 times per wk | 2.7% (111/4053) | 2.4% (13/538) | |
| Who manages your cholesterol‐lowering treatment? | <0.001 | ||
| Primary care | 43.6% (1749/4010) | 10.4% (54/518) | |
| Cardiologist | 35.9% (1440/4010) | 60.6% (314/518) | |
| Multiple doctors | 2.4% (96/4010) | 8.9% (46/518) | |
| Other | 18.1% (725/4010) | 20.1% (104/518) | |
Data are presented as mean±SD or % (n/N). ASCVD indicates atherosclerotic cardiovascular disease; GOULD, Getting to an Improved Understanding of Low‐Density Lipoprotein Cholesterol and Dyslipidemia Management; LDL‐C, low‐density lipoprotein cholesterol; and PCSK9, proprotein convertase subtilisin/kexin type 9.